CTRI/2020/05/025217RecruitingNot Applicable
COVID-19 and cancer chemotherapy- collate data on treatment patterns, short-term outcomes and patient experience
Dr Bhawna Sirohi6 sites in 1 country200 target enrollmentStarted: May 29, 2020Last updated:
Conditions
Trial Snapshot
- Phase
- Not Applicable
- Status
- Recruiting
- Sponsor
- Enrollment
- 200
- Locations
- 6
- Primary Endpoint
- To describe change in cancer treatment patterns as a result of the pandemic
Study Overview
Brief Summary
The aim of this research is to prospectively understand what changes intreatment clinicians have done and how this has impacted patients care. Patients on chemotherapy will also fill in aquestionnaire to understand the impact COVID-19 has had on them. Our study doesnot include any changes in treatment strategy as this would be fairlysubjective and would vary from one clinicianto the other on a case to basis as multiple factors would influence theirdecision.
Study Design
- Study Type
- Observational
Eligibility Criteria
- Ages
- 0.18 Year(s) to 0.99 Year(s) (—)
- Sex
- All
Inclusion Criteria
- •All adult (more than 18 years of age) cancer patients currently on active chemotherapy treatment at Max Institute of Cancer Care.
Exclusion Criteria
- •Patients not able to give consent Patient less than 18 years age on the day of enrollment.
Outcomes
Primary Outcomes
To describe change in cancer treatment patterns as a result of the pandemic
Time Frame: 6 months from start of enrollment
Secondary Outcomes
- To assess impact on short-term morbidity(Assess impact on patient experience (questionnaire based))
Investigators
Study Sites (6)
Loading locations...
Similar Trials
Recruiting
Not Applicable
Impact of the Coronavirus (COVID-19) on Patients With CancerCOVID-19CancerNCT04330521Stanford University50
Terminated
Not Applicable
Screening of Cancer Patients to Assess Impact of COVID-19Covid-19CancerNCT04373005University Health Network, Toronto83
Completed
Not Applicable
An Observational Study, Called ROCURS, to Learn About COVID-19 Related Outcomes in People With Cancer Who Are Treated With Tyrosine Kinase Inhibitors (TKIs) Including Regorafenib or SorafenibSARS-CoV-2 InfectionMalignant Solid TumorsCoronavirus Disease 2019 (COVID-19)NCT05594147Bayer4,103
Active, not recruiting
Not Applicable
COVID-19 and Cancer Consortium RegistryInvasive Malignancy (Any Type)COVID-19NCT04354701Vanderbilt-Ingram Cancer Center19,275
Unknown
Not Applicable
COVID-19 in Cancer Patients: Evaluation of Clinical Course and Impact on Oncological Care Including BiobankingCOVIDCancerNCT04408339Universitätsklinikum Hamburg-Eppendorf500